Aclaris Therapeutics Company Profile (NASDAQ:ACRS)

About Aclaris Therapeutics

Aclaris Therapeutics logoAclaris Therapeutics, Inc. is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies in dermatology. The Company's drug candidate, A-101 is being developed as an in-office treatment for seborrheic keratosis, a non-cancerous skin tumor, as well as for other cutaneous indications, such as common warts. In addition, the Company is engaged in developing a portfolio of Janus Kinase (JAK) inhibitor compounds for the treatment of alopecia areata and other dermatological conditions. The Company's products A-201 and A-301 are indicated for the treatment of alopecia areata. The Company's A-101 product is entering Phase III clinical trials for the treatment of seborrheic keratosis and Phase II clinical trials for the treatment of common warts. The Company's A-201 and A-301 products are in pre- clinical stage.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ACRS
  • CUSIP:
Key Metrics:
  • Previous Close: $25.16
  • 50 Day Moving Average: $22.28
  • 200 Day Moving Average: $20.05
  • 52-Week Range: $10.99 - $33.88
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.11
  • P/E Growth: -0.13
  • Market Cap: $545.44M
  • Outstanding Shares: 21,415,000
Profitability:
  • Return on Equity: -72.43%
  • Return on Assets: -51.65%
Debt:
  • Current Ratio: 17.39%
  • Quick Ratio: 17.39%
Additional Links:
Companies Related to Aclaris Therapeutics:

Analyst Ratings

Consensus Ratings for Aclaris Therapeutics (NASDAQ:ACRS) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $31.25 (22.02% upside)

Analysts' Ratings History for Aclaris Therapeutics (NASDAQ:ACRS)
Show:
DateFirmActionRatingPrice TargetDetails
9/30/2016JMP SecuritiesInitiated CoverageOutperformView Rating Details
9/19/2016Jefferies GroupBoost Price TargetBuy$23.00 -> $31.00View Rating Details
6/10/2016GuggenheimInitiated CoverageBuy$35.00View Rating Details
3/16/2016Citigroup Inc.Lower Price TargetBuy$34.00 -> $29.00View Rating Details
11/2/2015William BlairInitiated CoverageOutperform$30.00View Rating Details
(Data available from 9/30/2014 forward)

Earnings

Earnings History for Aclaris Therapeutics (NASDAQ:ACRS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/16/2016        
8/11/2016Q2($0.61)($0.62)ViewListenView Earnings Details
5/11/2016Q1($0.50)($0.65)ViewListenView Earnings Details
3/23/2016Q4($0.40)($0.28)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aclaris Therapeutics (NASDAQ:ACRS)
Current Year EPS Consensus Estimate: $-2.61 EPS
Next Year EPS Consensus Estimate: $-2.81 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.54)($0.54)($0.54)
Q3 20161($0.69)($0.69)($0.69)
Q4 20161($0.78)($0.78)($0.78)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aclaris Therapeutics (NASDAQ:ACRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Aclaris Therapeutics (NASDAQ:ACRS)
Insider Ownership Percentage: 46.40%
Institutional Ownership Percentage: 71.39%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/28/2016Kamil Ali-JacksonInsiderSell1,841$24.66$45,399.06View SEC Filing  
9/16/2016Ra Capital Management, LlcMajor ShareholderSell525,550$24.19$12,713,054.50View SEC Filing  
8/26/2016Kamil Ali-JacksonInsiderSell3,738$20.35$76,068.30View SEC Filing  
2/23/2016Ra Capital Management, LlcMajor ShareholderBuy39,726$17.15$681,300.90View SEC Filing  
1/20/2016Ra Capital Management, LlcMajor ShareholderBuy7,803$19.87$155,045.61View SEC Filing  
1/13/2016Ra Capital Management, LlcMajor ShareholderBuy15,637$19.10$298,666.70View SEC Filing  
10/29/2015Ra Capital Management, LlcMajor ShareholderBuy244,200$14.00$3,418,800.00View SEC Filing  
10/22/2015Ra Capital Management, LlcMajor ShareholderBuy5,410$14.03$75,902.30View SEC Filing  
10/21/2015Ra Capital Management, LlcMajor ShareholderBuy34,999$14.89$521,135.11View SEC Filing  
10/14/2015Ra Capital Management, LlcMajor ShareholderBuy42,813$14.06$601,950.78View SEC Filing  
10/13/2015Albert ChaDirectorBuy454,545$11.00$4,999,995.00View SEC Filing  
10/13/2015Fmr LlcInsiderBuy335,455$11.00$3,690,005.00View SEC Filing  
10/13/2015Sofinnova Venture Partners ViiMajor ShareholderBuy409,090$11.00$4,499,990.00View SEC Filing  
10/8/2015Ra Capital Management, LlcMajor ShareholderBuy2,237,130$10.86$24,295,231.80View SEC Filing  
10/7/2015Vivo Ventures Vii, LlcMajor ShareholderBuy13,352$11.00$146,872.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Aclaris Therapeutics (NASDAQ:ACRS)
DateHeadline
streetinsider.com logoForm 424B3 Aclaris Therapeutics, (NASDAQ:ACRS)
www.streetinsider.com - September 13 at 3:17 PM
biz.yahoo.com logoACLARIS THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:ACRS)
biz.yahoo.com - September 13 at 3:17 PM
finance.yahoo.com logoAclaris Therapeutics to Present at the Morgan Stanley 2016 Healthcare Conference (NASDAQ:ACRS)
finance.yahoo.com - September 6 at 8:03 AM
4-traders.com logoAclaris Therapeutics : Announces Positive Results in Phase 2 Clinical Trial of A-101 for Treatment of Common Warts (NASDAQ:ACRS)
www.4-traders.com - August 19 at 11:32 AM
finance.yahoo.com logoAclaris (ACRS) Common Warts Candidate Positive in Phase II (NASDAQ:ACRS)
finance.yahoo.com - August 19 at 11:32 AM
streetinsider.com logoAclaris Therapeutics (ACRS) Announces Statistically Significant Data from A-101 Phase 2 as Common Warts Treatment (NASDAQ:ACRS)
www.streetinsider.com - August 18 at 11:41 AM
finance.yahoo.com logo7:30 am Aclaris Therapeutics announces 'positive' results from its Phase 2 clinical trial of A-101 Topical solution; achieves primary and secondary endpoints (NASDAQ:ACRS)
finance.yahoo.com - August 18 at 11:41 AM
finance.yahoo.com logoAclaris Therapeutics Announces Positive Results in Phase 2 Clinical Trial of A-101 for Treatment of Common Warts (NASDAQ:ACRS)
finance.yahoo.com - August 18 at 11:41 AM
finance.yahoo.com logoEdited Transcript of ACRS earnings conference call or presentation 11-Aug-16 12:30pm GMT (NASDAQ:ACRS)
finance.yahoo.com - August 11 at 9:07 PM
finance.yahoo.com logoAclaris reports 2Q loss (NASDAQ:ACRS)
finance.yahoo.com - August 11 at 12:16 PM
globenewswire.com logoAclaris Therapeutics Reports Second Quarter 2016 Financial Results (NASDAQ:ACRS)
globenewswire.com - August 11 at 12:16 PM
finance.yahoo.com logoAclaris Announces Appointment of Bill Humphries to Board of Directors (NASDAQ:ACRS)
finance.yahoo.com - August 4 at 9:00 PM
biz.yahoo.com logoACLARIS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure (NASDAQ:ACRS)
biz.yahoo.com - August 4 at 9:00 PM
finance.yahoo.com logoAclaris Therapeutics to Announce Second Quarter 2016 Financial Results on August 11, 2016 (NASDAQ:ACRS)
finance.yahoo.com - August 2 at 8:02 AM
4-traders.com logoNasdaq : Notches Greater Revenue Across All Its Units (NASDAQ:ACRS)
www.4-traders.com - July 27 at 11:56 AM
4-traders.com logoCommerceHub (Nasdaq: CHUBA, CHUBK) to Ring The Nasdaq Stock Market Opening Bell (NASDAQ:ACRS)
www.4-traders.com - July 26 at 3:19 PM
finance.yahoo.com logoAclaris Therapeutics Completes Enrollment of Phase 3 Pivotal Trials of A-101 for the Treatment of Seborrheic Keratosis (SK); Provides Update on Clinical Programs (NASDAQ:ACRS)
finance.yahoo.com - July 25 at 8:00 AM
finance.yahoo.com logoAclaris Therapeutics to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference (NASDAQ:ACRS)
finance.yahoo.com - July 5 at 8:39 AM
biz.yahoo.com logoACLARIS THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:ACRS)
biz.yahoo.com - June 29 at 4:08 PM
finance.yahoo.com logoCoverage initiated on Aclaris Therapeutics by Guggenheim (NASDAQ:ACRS)
finance.yahoo.com - June 10 at 6:22 AM
biz.yahoo.com logoACLARIS THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equit (NASDAQ:ACRS)
biz.yahoo.com - June 2 at 4:18 PM
finance.yahoo.com logoAclaris Therapeutics to Present at Upcoming Investor Conferences in June (NASDAQ:ACRS)
finance.yahoo.com - May 31 at 8:48 AM
marketexclusive.com logoBiotech Movers and Shakers: Aclaris Therapeutics Inc (NASDAQ:ACRS) and XenoPort, Inc. (NASDAQ:XNPT) - Market Exclusive (NASDAQ:ACRS)
marketexclusive.com - May 24 at 11:55 AM
tradecalls.org logoRevenue Update on Aclaris Therapeutics Inc(NASDAQ:ACRS) - Trade Calls (NASDAQ:ACRS)
www.tradecalls.org - May 21 at 12:35 PM
News IconWere Analysts Bearish Aclaris Therapeutics Inc (NASDAQ:ACRS) This Week? - Wall Street Hints and News (NASDAQ:ACRS)
hintsnewsnetwork.com - May 20 at 12:28 PM
fxpips.com logoHot Stocks – ACIA, HTGM, LINK, NVDA, AIQ, ACRS, CXRX (NASDAQ:ACRS)
www.fxpips.com - May 16 at 11:51 AM
blogs.barrons.com logoWhy Pfizer's Anacor Purchase is Good News for Dermira, Aclaris (NASDAQ:ACRS)
blogs.barrons.com - May 16 at 10:54 AM
marketexclusive.com logoThe Week's Big Biotech Losers: Aclaris Therapeutics Inc (NASDAQ:ACRS) and Inotek Pharmaceuticals Corp (NASDAQ ... - Market Exclusive (NASDAQ:ACRS)
marketexclusive.com - May 12 at 11:36 AM
finance.yahoo.com logoEdited Transcript of ACRS earnings conference call or presentation 11-May-16 12:30pm GMT (NASDAQ:ACRS)
finance.yahoo.com - May 11 at 7:25 PM
biz.yahoo.com logoAclaris Therapeutics Inc Earnings Call scheduled for 8:30 am ET today (NASDAQ:ACRS)
biz.yahoo.com - May 11 at 8:30 AM
biz.yahoo.com logoACLARIS THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an (NASDAQ:ACRS)
biz.yahoo.com - May 11 at 7:32 AM
sg.finance.yahoo.com logoAclaris reports 1Q loss (NASDAQ:ACRS)
sg.finance.yahoo.com - May 11 at 7:07 AM
biz.yahoo.com logoQ1 2016 Aclaris Therapeutics Inc Earnings Release - Before Market Open (NASDAQ:ACRS)
biz.yahoo.com - May 11 at 7:07 AM
finance.yahoo.com logoAclaris Therapeutics Reports First Quarter 2016 Financial Results (NASDAQ:ACRS)
finance.yahoo.com - May 11 at 7:00 AM
News IconInnovus Pharma (INNV): Targeting $3+ Billion Markets with 13 Commercial Products (NASDAQ:ACRS)
secfilings.com - May 10 at 11:56 AM
finance.yahoo.com logoDrug Stocks Q1 Earnings Slated on May 11: ACRS, EARS & More (NASDAQ:ACRS)
finance.yahoo.com - May 10 at 11:56 AM
News IconAclaris Therapeutics Incorporated (NASDAQ:ACRS) Sellers Increased By 4.01% Their Shorts - B.O.D.Y Confidential (NASDAQ:ACRS)
www.bodyconfidential.com - May 5 at 11:59 AM
finance.yahoo.com logoAclaris Therapeutics, Inc. Appoints Kevin Scott as Vice President of Sales (NASDAQ:ACRS)
finance.yahoo.com - May 5 at 8:25 AM
nasdaq.com logoAclaris Therapeutics to Present at the Bank of America Merrill Lynch 2016 Healthcare Conference - Nasdaq (NASDAQ:ACRS)
www.nasdaq.com - May 3 at 11:30 AM
finance.yahoo.com logoAclaris Therapeutics to Present at the Bank of America Merrill Lynch 2016 Healthcare Conference (NASDAQ:ACRS)
finance.yahoo.com - May 2 at 4:05 PM
News IconAfter Last Week What Do Analysts Think Of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Share Trading News (NASDAQ:ACRS)
www.sharetrading.news - April 27 at 12:26 PM
finance.yahoo.com logoAclaris Therapeutics to Announce First Quarter 2016 Financial Results on May 11, 2016 (NASDAQ:ACRS)
finance.yahoo.com - April 26 at 4:05 PM
News IconAclaris Therapeutics Incorporated (NASDAQ:ACRS) Shorted Shares Increased 1.82% After Market Selling (NASDAQ:ACRS)
www.bibeypost.com - April 25 at 11:59 AM
News IconAclaris Therapeutics, Inc. (NASDAQ:ACRS) Updated Broker Ratings - Risers & Fallers (NASDAQ:ACRS)
www.risersandfallers.com - April 22 at 12:08 PM
News IconAclaris Therapeutics Incorporated (NASDAQ:ACRS) Sellers Increased By 1.82% Their Shorts - Stock Caller (NASDAQ:ACRS)
www.stockcaller.com - April 15 at 11:46 AM
News IconLatest Analyst Ratings For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Share Trading News (NASDAQ:ACRS)
www.sharetrading.news - April 14 at 11:35 AM
News IconRecently Changed Price Targets On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Risers & Fallers (NASDAQ:ACRS)
www.risersandfallers.com - April 9 at 11:00 AM
blogs.barrons.com logoIf Valeant Sells Bausch & Lomb, Will Allergan Be a Bidder? (NASDAQ:ACRS)
blogs.barrons.com - April 8 at 2:51 PM
News IconWhat Next for Aclaris Therapeutics Inc Stock After Today's Huge Decline? - Stock Caller (NASDAQ:ACRS)
www.stockcaller.com - April 6 at 11:18 AM
News IconAnalyst Coverage: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Risers & Fallers (NASDAQ:ACRS)
www.risersandfallers.com - April 5 at 10:52 AM

Social

Aclaris Therapeutics (NASDAQ:ACRS) Chart for Friday, September, 30, 2016


Last Updated on 9/30/2016 by MarketBeat.com Staff